Clinical trial · Observational
Venetoclax Registry
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax: The Venetoclax Registry
NCT03662724CI-TRIAL-00050077VENregunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Venetoclax | Drug | Venetoclax | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall response rate of Venetoclax treatment.
- timeFrame
- 4 months
- description
- Overall response rate of Venetoclax treatment (complete remission, complete remission with incomplete regeneration, partial remission)
Secondary outcomes (3)
- measure
- Event-free survival during Venetoclax treatment
- timeFrame
- 5 years
- description
- Event-free survival of patients with relapsed/refractory AML receiving Venetoclax
- measure
- Relapse-free survival during Venetoclax treatment
- timeFrame
- 5 years
- description
- Relapse-free survival of patients with relapsed/refractory AML receiving Venetoclax
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: relapsed/refractory AML Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.